Trials / Unknown
UnknownNCT03941457
Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Asclepius Technology Company Group (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK cell immunotherapy for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BiCAR-NK cells (ROBO1 CAR-NK cells) | The subject will be observed for any side effects during this time and all the adverse events will be recorded. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-05-01
- Completion
- 2022-05-01
- First posted
- 2019-05-08
- Last updated
- 2019-05-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03941457. Inclusion in this directory is not an endorsement.